1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Clene Inc.

Clene Inc.

CLNNW
Clene Inc.US flagNASDAQ Capital Market
0.00
USD
+0.00
- -
2.16MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
1
- -
1
- -
- -
- -
Operating Margin (%)
- -
-7,337.38
-6,262.24
-9,420.08
-5,850.15
-9,349.42
-10,908
-14,878.36
Depreciation Expense
1
1
1
1
2
2
1
1
Net Income, GAAP
-16
-19
-10
-30
-50
-39
-26
-34
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-9,357.77
-1,347.16
-6,325.16
-7,569.42
-11,520.47
-13,086.5
-25,009.7
Working Capital
5
51
49
15
14
6
-2
6
LT Debt
2
4
24
25
12
20
17
19
Total Equity
-68
- -
13
3
13
-9
-18
-19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
5
3
LT Borrowings
16
14
16
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
11
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13
9
13
Cash, Cash Equivalents & STI
8
5
6
Accounts Receivable, Net
- -
- -
3
Inventories
- -
- -
- -
Total Current Liabilities
8
11
7
Payables & Accruals
2
1
2
ST Debt
2
5
3
Deferred Revenue
1
2
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
753.19%
98.62%
Free Cash Flow
- -
7.03%
-12.91%
Net Income, GAAP
- -
33.84%
-33.57%
Sales/Revenue/Turnover
- -
33.09%
-41.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert Etherington
Full Time Employees
75
Sector
Healthcare
Industry
Biotechnology
Address
6550 South Millrock Drive Salt Lake City UT United States of America 84121
IPO Date
Oct 18, 2018
CIK
0001822791
Website
clene.com
Similar Companies
Apollomics, Inc. (APLMW)
Macrogen, Inc. (038290.KQ)
Orthocell Limited (OCC.AX)
Organicell Regenerative Medicine, Inc. (BPSR)
Constellation Pharmaceuticals, Inc. (CNST)
Sigilon Therapeutics, Inc. (SGTX)
Business
Clene Inc. is a late clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics aimed at treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. The company's core product pipeline includes CNM-Au8, an oral suspension of gold nanocrystals designed to restore neuronal health and function by enhancing cellular energy production and reducing oxidative stress; CNM-ZnAg, a broad-spectrum antiviral agent composed of silver and zinc nanocrystals targeting infectious diseases and wound healing; and CNM-AgZn17, a gel polymer suspension of zinc and silver ions also aimed at infectious disease treatment. Clene operates through its wholly owned subsidiary Clene Nanomedicine Inc., leveraging its electro-crystal-chemistry drug platform to produce stable nanocrystal suspensions for therapeutic use. Founded in 2020 and headquartered in Salt Lake City, Utah, Clene serves a global biopharmaceutical market focused on high unmet medical needs in neurodegenerative and infectious diseases. Recent major developments include the completion of FDA-recommended biomarker analyses for CNM-Au8 in ALS patients, demonstrating statistically significant reductions in disease biomarkers supporting potential disease-modifying effects. Clene plans to submit a New Drug Application (NDA) for CNM-Au8 under the FDA's accelerated approval pathway in the first quarter of 2026, with a Phase 3 RESTORE-ALS trial planned as the post-approval confirmatory study. The company hosted an investor call in December 2025 to update on the CNM-Au8 program and continues to invest in expanding its nanotherapeutics pipeline designed to improve mitochondrial health and protect neuronal function. Clene's technology platform and clinical-stage assets position it as an innovative player in the biotechnology sector with a focused strategy on addressing neurodegenerative and infectious diseases worldwide.